<DOC>
	<DOC>NCT02727907</DOC>
	<brief_summary>Study design is double-blind, randomized, placebo-controlled study in 3 parallel groups with the use of active comparator and placebo. Total duration of therapy of about 2 years. Study hypothesis is equivalence of efficacy and safety of the investigational drug BCD-033 original drug RebifÂ®.</brief_summary>
	<brief_title>Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>1. Age 1855 2. Patients of both genders with Multiple Sclerosis (McDonald criteria 2010) 3. No relapses 28 days before randomisation 4. Expanded Disability Status Scale score 05,5 Exclusion Criteria 1. Primary or secondary progression of Multiple Sclerosis 2. Expanded Disability Status Scale score more then 5,5 3. Severe depression, suicide ideas and/or attempts 4. Systemic corticosteroid application in 30 days before randomisation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>